Kate LaRiviere Homer1, Jeffrey Warren2, Dmitry Karayev3, Puja P Khanna4, Amber Young, Vivek Nagaraja, Allan L Metzger3, Dinesh Khanna. 1. From the University of Michigan Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan. 2. Department of Pathology, University of Michigan Medical School, Ann Arbor, MI. 3. RDL Reference Laboratory, Los Angeles, CA. 4. Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Abstract
BACKGROUND/ OBJECTIVE: The criterion standard for anti-topoisomerase I antibody (anti-topo I antibody) testing in systemic sclerosis (SSc) uses immunodiffusion (ID) techniques, but enzyme-linked immunosorbent assay (ELISA) and multiple-bead technology are often used in current settings to save time and cost. Our aim was to assess the performance of the multiple-bead assay, ELISA, and ID testing methods. METHODS: We conducted a retrospective study of patients at the University of Michigan whose extractable nuclear antigen 10 autoantibody panel tested positive for the anti-topo I antibody by multiple-bead technology during a 1-year period. All samples positive by multiple-bead assay were sent to the RDL Laboratories and reflexed for ELISA, and all anti-topo I antibodies positive by ELISA were further tested by ID. Clinical data were reviewed by a rheumatologist and assessed for presence of SSc. Data were analyzed via frequency tables. RESULTS: Approximately 9500 extractable nuclear antigen 10 panels were ordered by physicians at the University of Michigan. Of these, 129 patients were positive for the anti-topo I antibody by multiple-bead assay, 51 were positive by multiple-bead assay and ELISA, and 21 were positive by multiple-bead assay, ELISA, and ID. We found that 26.4% of patients positive by multiple-bead assay, 47.1% positive by multiple-bead assay and ELISA, and 95.2% positive by multiple-bead assay, ELISA, and ID had SSc. CONCLUSIONS: Multiple-bead assays have a high rate of false-positive results for the anti-topo I antibody in patients without clinical evidence of SSc. A stepwise approach of confirmation of positive multiple-bead assay results using both ELISA and ID improves the predictive value of antibody testing for the diagnosis of SSc.
BACKGROUND/ OBJECTIVE: The criterion standard for anti-topoisomerase I antibody (anti-topo I antibody) testing in systemic sclerosis (SSc) uses immunodiffusion (ID) techniques, but enzyme-linked immunosorbent assay (ELISA) and multiple-bead technology are often used in current settings to save time and cost. Our aim was to assess the performance of the multiple-bead assay, ELISA, and ID testing methods. METHODS: We conducted a retrospective study of patients at the University of Michigan whose extractable nuclear antigen 10 autoantibody panel tested positive for the anti-topo I antibody by multiple-bead technology during a 1-year period. All samples positive by multiple-bead assay were sent to the RDL Laboratories and reflexed for ELISA, and all anti-topo I antibodies positive by ELISA were further tested by ID. Clinical data were reviewed by a rheumatologist and assessed for presence of SSc. Data were analyzed via frequency tables. RESULTS: Approximately 9500 extractable nuclear antigen 10 panels were ordered by physicians at the University of Michigan. Of these, 129 patients were positive for the anti-topo I antibody by multiple-bead assay, 51 were positive by multiple-bead assay and ELISA, and 21 were positive by multiple-bead assay, ELISA, and ID. We found that 26.4% of patients positive by multiple-bead assay, 47.1% positive by multiple-bead assay and ELISA, and 95.2% positive by multiple-bead assay, ELISA, and ID had SSc. CONCLUSIONS: Multiple-bead assays have a high rate of false-positive results for the anti-topo I antibody in patients without clinical evidence of SSc. A stepwise approach of confirmation of positive multiple-bead assay results using both ELISA and ID improves the predictive value of antibody testing for the diagnosis of SSc.
Authors: Petra Eissfeller; Michael Sticherling; Dietmar Scholz; Kirsten Hennig; Tanja Lüttich; Manfred Motz; Arno Kromminga Journal: Ann N Y Acad Sci Date: 2005-06 Impact factor: 5.691
Authors: Thomas B Martins; Rufus Burlingame; Carlos A von Mühlen; Troy D Jaskowski; Christine M Litwin; Harry R Hill Journal: Clin Diagn Lab Immunol Date: 2004-11
Authors: I E A Hoffman; I Peene; L Meheus; T W J Huizinga; L Cebecauer; D Isenberg; K De Bosschere; F Hulstaert; E M Veys; F De Keyser Journal: Ann Rheum Dis Date: 2004-09 Impact factor: 19.103
Authors: Bochra Jandali; Gloria A Salazar; Marie Hudson; Marvin J Fritzler; Marka A Lyons; Rosa M Estrada-Y-Martin; Julio Charles; Katherine A Terracina; Maureen D Mayes; Shervin Assassi Journal: ACR Open Rheumatol Date: 2022-01-20